Jose Alberto Halperin

This inventor holds 36 USPTO granted patents and 9 published patent applications, plus 5 CIPO patents and 6 EPO patents, primarily in Biotechnology Innovations. Top assignees: Harvard College, Children's Medical Center Corporation, Best Doctors, Inc.. Active years: 1994-2024.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Jose Alberto Halperin. Retrieved from https://idiyas.com/inventor/jose-alberto-halperin

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 36 (Patent Applications = 9)

% Patents Active = 80.6

CIPO Patents = 5 (Patent Applications = 4)

EPO Patents = 6 (Patent Applications = 4)

Average Co-Inventor Count = 1.9

ph-index = 10

Forward Citations = 331(Granted Patents)

Company Filing History:

Children's Medical Center Corporation

Ion Pharmaceuticals, Inc.

patents

5. 2 out of 2

Nuchem Pharmaceuticals Inc.

7. 2 out of 834,570

Other

patents

where one patent can have more than one assignee

Years Active: 1994-2024

Loading Chart...

Areas of Expertise:

Glycated CD59 Peptides

Anti-CD59 Antibodies

Diabetes Treatments

Quality Control Bioassays

Mass Spectrometric Methods

Cell Proliferation Inhibition

Medical Consultation Management

Drug Delivery Systems

Neovascularization Treatments

Inflammatory Disease Therapies

Nutraceutical Products

Epithelial Lesion Treatments

36 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 11891448 - Glycated CD59 peptides, their preparation, and uses thereof (2024-02-06),

2. 11866506 - Anti-CD59 antibodies (2024-01-09),

3. 11161910 - Glycated CD59 peptides, their preparation, and uses thereof (2021-11-02),

4. 10732186 - Methods and reagents for the assessment of gestational diabetes (2020-08-04),

5. 10309973 - Surrogates of post-translationally modified proteins and uses thereof (2019-06-04),

6. 9952200 - Cell based quality control bioassays for nutriceutical and medicinal products (2018-04-24),

7. 9417248 - Surrogates of post-translationally modified proteins and uses thereof (2016-08-16),

8. 9410946 - Quality control bioassays for nutriceutical and medicinal products (2016-08-09),

9. 9068006 - Glycated CD59 peptides, their preparation, and uses thereof (2015-06-30),

10. 8999646 - Quality control bioassays for nutriceutical and medicinal products (2015-04-07),

11. 8969573 - Compounds for the inhibition of cellular proliferation (2015-03-03),

12. 8404451 - Mass spectrometric methods and products (2013-03-26),

13. 8298779 - Methods, products and treatments for diabetes (2012-10-30),

14. 8093009 - Mass spectrometric methods and products (2012-01-10),

15. 8008024 - Methods, products and treatments for diabetes (2011-08-30),

Title: Jose Alberto Halperin: Innovator in Diabetes Research

Introduction

Jose Alberto Halperin, based in Brookline, MA, is a prominent inventor with an impressive portfolio of 36 patents focused on advancements in diabetes research and diagnostics. His contributions to the field underscore his commitment to finding innovative solutions to critical health challenges.

Latest Patents

Among his latest inventions is a patent for "Glycated CD59 peptides, their preparation, and uses thereof." This invention encompasses glycated Amadori products of the CD59 peptide, which serve as valuable tools for diagnosing and prognosing pre-diabetes and diabetes. Notable aspects of this invention include methodologies for generating antibodies and antibody fragments related to glycated CD59. Furthermore, Halperin's related patent for anti-CD59 antibodies encompasses various diagnostics, kits, and assessment methods aimed at diabetes-related indications, including avenues for evaluating inhibitors of CD59 glycation.

Career Highlights

Halperin has held significant positions at prestigious organizations, including the President and Fellows of Harvard College and the Children's Medical Center Corporation. His research and inventions have made substantial impacts in medical science, particularly in understanding and addressing diabetes.

Collaborations

Throughout his career, Halperin has collaborated with notable peers, including Carlo Brugnara and Michael Chorev. These partnerships have fostered a dynamic exchange of ideas and innovations, contributing to the development of groundbreaking technologies in the field.

Conclusion

Jose Alberto Halperin continues to be a guiding force in diabetes research through his innovative patents and collaborations. His work not only advances scientific understanding but also holds the potential to transform diabetes diagnostics and treatment, ultimately improving patient care and health outcomes.

Profile summary based on public USPTO records.